Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) EBIT Margin (2020 - 2025)

Bioventus' EBIT Margin history spans 6 years, with the latest figure at 12.34% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 733.0% year-over-year to 12.34%; the TTM value through Dec 2025 reached 9.5%, up 1215.0%, while the annual FY2025 figure was 9.5%, 1215.0% up from the prior year.
  • EBIT Margin reached 12.34% in Q4 2025 per BVS's latest filing, up from 8.12% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 26.9% in Q2 2021 to a low of 98.58% in Q4 2022.
  • Average EBIT Margin over 5 years is 7.77%, with a median of 1.43% recorded in 2023.
  • Peak YoY movement for EBIT Margin: tumbled -9762bps in 2022, then skyrocketed 10058bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 2.42% in 2021, then tumbled by -414bps to 12.43% in 2022, then surged by 107bps to 0.86% in 2023, then surged by 483bps to 5.01% in 2024, then soared by 146bps to 12.34% in 2025.
  • Per Business Quant, the three most recent readings for BVS's EBIT Margin are 12.34% (Q4 2025), 8.12% (Q3 2025), and 12.44% (Q2 2025).